Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia

Ting Yen Chiang, Ling Yuh Shyu, Thomas Chang Yao Tsao, Ming Hsien Chien, Shih Ming Tsao, Yuan Ti Lee, Shun Fa Yang

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.

原文英語
頁(從 - 到)449-454
頁數6
期刊Clinical Chemistry and Laboratory Medicine
50
發行號3
DOIs
出版狀態已發佈 - 三月 1 2012

指紋

Matrix Metalloproteinase 9
Polymorphism
Pneumonia
Plasmas
Proteins
Single Nucleotide Polymorphism
Nucleotides
Genes
Immunosorbents
Polymerase chain reaction
Leukocyte Count
Restriction Fragment Length Polymorphisms
Assays
Neutrophils
Blood
Biomarkers
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Genotype
Cells

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

引用此文

Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. / Chiang, Ting Yen; Shyu, Ling Yuh; Tsao, Thomas Chang Yao; Chien, Ming Hsien; Tsao, Shih Ming; Lee, Yuan Ti; Yang, Shun Fa.

於: Clinical Chemistry and Laboratory Medicine, 卷 50, 編號 3, 01.03.2012, p. 449-454.

研究成果: 雜誌貢獻文章

Chiang, Ting Yen ; Shyu, Ling Yuh ; Tsao, Thomas Chang Yao ; Chien, Ming Hsien ; Tsao, Shih Ming ; Lee, Yuan Ti ; Yang, Shun Fa. / Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. 於: Clinical Chemistry and Laboratory Medicine. 2012 ; 卷 50, 編號 3. 頁 449-454.
@article{62ec33e8b7234b81a5dfbfd9d0f1512c,
title = "Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia",
abstract = "Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.",
keywords = "community-acquired pneumonia, gene polymorphism, metalloproteinase-9 (MMP-9)",
author = "Chiang, {Ting Yen} and Shyu, {Ling Yuh} and Tsao, {Thomas Chang Yao} and Chien, {Ming Hsien} and Tsao, {Shih Ming} and Lee, {Yuan Ti} and Yang, {Shun Fa}",
year = "2012",
month = "3",
day = "1",
doi = "10.1515/cclm.2011.805",
language = "English",
volume = "50",
pages = "449--454",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "3",

}

TY - JOUR

T1 - Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia

AU - Chiang, Ting Yen

AU - Shyu, Ling Yuh

AU - Tsao, Thomas Chang Yao

AU - Chien, Ming Hsien

AU - Tsao, Shih Ming

AU - Lee, Yuan Ti

AU - Yang, Shun Fa

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.

AB - Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.

KW - community-acquired pneumonia

KW - gene polymorphism

KW - metalloproteinase-9 (MMP-9)

UR - http://www.scopus.com/inward/record.url?scp=84860435518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860435518&partnerID=8YFLogxK

U2 - 10.1515/cclm.2011.805

DO - 10.1515/cclm.2011.805

M3 - Article

C2 - 22107133

AN - SCOPUS:84860435518

VL - 50

SP - 449

EP - 454

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 3

ER -